

UNiTY



The newsletter of the Global Lung Cancer Coalition

Spring 26

02 Latest patient experience survey results reveal encouraging trends

03 Special Recognition Awards presented by our Portuguese and Greek members

04 GO2 for Lung Cancer launches new guide for lung cancer navigators and AHPs

09 Step-by-step guide on how to create a successful email fundraising campaign

WELCOME

In 2001, nine organisations with an interest in lung cancer came together and formed the Global Lung Cancer Coalition.

In our 25th anniversary year, the GLCC now comprises of 44 non-government patient organisations from around the world.

Our aims are to increase awareness of lung cancer issues, change perceptions of lung cancer, help people with lung cancer access the information and support they need, and push governments and legislative bodies to improve treatment and care.

Already, we have achieved a lot. But we also know that much more must be done to improve the outcomes and lives of people affected by lung cancer – something we are determined to do.



To join us, please read our membership criteria, and download a membership application form at lungcancercoalition.org

NEW BIOMARKER DATABASE TO SUPPORT PEOPLE WITH LUNG CANCER



The GLCC has launched a new online database bringing together groups and organisations dedicated to supporting people whose lung cancer is driven by specific, targetable biomarkers.

The database highlights organisations focused on a range of biomarkers – also known as oncogenes – including ALK+, EGFR+, BRAF, KRAS, Exon 20, MET, RET, NTRK and ROS1.


The resource also features wider organisations that provide information, advocacy and support for people affected by biomarker-driven lung cancers.


Biomarker testing plays a crucial role in modern lung cancer care. By identifying specific changes in cancer cells that cause tumours to grow and spread, testing helps clinicians determine the most effective treatment options.

This is particularly important for people diagnosed with non-small cell lung cancer (NSCLC), and especially lung adenocarcinoma, where targeted therapies can significantly improve outcomes.

The new resource is designed to help patients, carers and healthcare professionals easily find relevant information and peer support tailored to specific biomarker types.

The GLCC is committed to keeping the database comprehensive and up to date. We invite members to email glcc@roycastle.org with details of biomarker-driven NSCLC groups not currently listed.

 **Please click here to find out more.**

 **Please click here to read an explainer from GO2 for Lung Cancer on how genetic mutations, changes or abnormalities drive specific types of non-small cell lung cancer.**

LATEST PATIENT EXPERIENCE SURVEY REVEALS ENCOURAGING TRENDS



A reminder to members that all the findings from the GLCC's sixth annual global patient experience survey are available on our [website](#).

You can download global findings in a PDF or Word document format, and an Excel spreadsheet outlining questions and patients' responses.

National infographics can also be downloaded for the following countries:

Argentina, Australia, Brazil, Canada, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Mexico, Portugal, South Africa, Spain, Taiwan, UK and USA.

This year's patient experience survey revealed some encouraging trends. Many patients reported feeling actively involved in decisions about their treatment and care, with the majority receiving information at appropriate times and support that broadly met their needs.

However, the findings also highlight a clear need to strengthen communication with patients around key aspects of care, particularly diagnostic testing and the implications of different test results.

The survey further emphasises the importance of encouraging and equipping treatment and support teams to recognise and accommodate patient preferences at every stage of the care pathway.

GLCC LAUNCHES UPDATED E-ATLAS



The GLCC has launched an updated version of its E-Atlas, a unique online tool providing a global snapshot of lung cancer data, policy and progress.

The revised E-Atlas supports advocates, researchers and policymakers in understanding lung cancer trends within and between countries.

It brings together six key indicators: incidence, mortality, survival, the existence of a national cancer plan, the presence of a cancer registry, and implementation of the World Health Organization's Framework Convention on Tobacco Control.

By enabling users to explore and compare data across countries, the E-Atlas highlights gaps in prevention, diagnosis and care, helping to drive evidence-based advocacy and policy change.

Insights from the latest update show that, despite growing political momentum around lung cancer in recent years, this has not consistently translated into reductions in incidence and mortality worldwide.

Denmark, for example, has seen a steady decline in both measures, while India has experienced increases, despite having a lower overall lung cancer burden than many European and North American countries.

While data alone cannot explain these trends, it provides an important point for reflection alongside policy and social factors.

The E-Atlas also allows users to compare trends over time, offering insights into how different policies may influence outcomes.

The GLCC hopes the updated E-Atlas will support campaigners and policymakers in improving lung cancer outcomes worldwide.

It also comes as countries respond to renewed global commitments to lung health, including the recent WHO resolution *Promoting and prioritizing an integrated approach to lung health*.



Please click here to find out more about lung cancer trends in your country.

GOOGLE TRANSLATE

Articles marked Google Translate have been translated from a non-English news story. This means you may need to paste the story into Google Translate and select your appropriate language.



CELEBRATE 25 YEARS OF THE GLCC WITH US

To celebrate 25 years of the GLCC in 2026, we're producing a special edition of the *Unity* newsletter.

This edition will feature 25 quotes from people connected to the GLCC, sharing what the organisation means to them.

If you'd like to contribute, please email glcc@roycastle.org with your thoughts about the GLCC.

While we may not be able to include every submission in the newsletter, all quotes will be featured on the GLCC website.

SPECIAL RECOGNITION AWARDS PRESENTED

Pulmonale, the Portuguese Lung Cancer Association, has announced Professor Eduardo Carqueja as the recipient of its 2025 Special Recognition Award.

Presented annually with the support of the GLCC, the Special Recognition Award celebrates individuals and organisations that have made significant strides in addressing lung cancer stigma, promoting early detection and advocating for equitable access to high-quality care.

Professor Carqueja was selected for his long-standing commitment to health communication. His work has been instrumental in bridging the gap between clinical knowledge and the public, ensuring that patients and their families have access to clear, reliable and empathetic information.

Pulmonale highlighted that the award underscores the critical role of education in the fight against lung cancer. By championing health literacy, Professor Carqueja has empowered citizens to make informed decisions about their health, while actively challenging the fear and misinformation that often surround a lung cancer diagnosis.

This initiative reinforces the shared mission of Pulmonale and the GLCC: to transform lung cancer care and to celebrate individuals who drive positive change in their communities.



Please click here for more information about Pulmonale's work in Portugal.

FairLife Lung Cancer Care of Greece has presented a Special Recognition Award to Dimitris Katsioulas of Catalytica, a digital strategy and advertising agency.

The award recognises Catalytica's strategic leadership in shaping FairLife Lung Cancer Care's digital communication. Their work has transformed complex data and multi-platform outreach into clear, human-centred pathways that guide people from awareness to support.

Using a data-driven yet deeply empathetic approach, Catalytica has helped turn anonymous online searches into real requests for help. This has strengthened access to prevention, screening and psychosocial support for people affected by lung cancer.

The impact of this approach has been both tangible and measurable. FairLife Lung Cancer Care now reaches 25,190 social media followers and 3.2 million unique users across its digital platforms.

Presenting the award in collaboration with the GLCC was particularly significant for FairLife Lung Cancer Care. It highlights the vital role of responsible and ethical communication in lung cancer advocacy.

It also reinforces that impactful communication is a global priority in reducing stigma, improving awareness and supporting patients and caregivers worldwide.



Please click here for more information about FairLife Lung Cancer Care's work in Greece.

NEW GUIDE ON ROBOTIC-ASSISTED LUNG SURGERY


Roy Castle Lung Cancer Foundation has launched a new information booklet to help people better understand robotic-assisted lung surgery.

As advances in surgical care become increasingly available across the UK, the charity aims to ensure that everyone affected by lung cancer feels informed, confident and supported when making decisions about their treatment.



The new guide has been developed in collaboration with thoracic surgeons, lung cancer nurse specialists and people who have undergone robotic-assisted lung surgery. It provides clear, accessible information about how the procedure works and what patients can expect before, during and after surgery.

The booklet also outlines potential risks and side effects, answers common questions and concerns, and includes personal experiences from people who have had robotic-assisted lung surgery, helping to bring the information to life.

 [Please click here for more information about the new booklet and how to download it.](#)

NEW PROFESSIONAL FRAMEWORK FOR LUNG CANCER NAVIGATORS

Lung Cancer Nursing UK has launched a new professional development framework for lung cancer navigators and coordinators, designed to strengthen professional development and improve lung cancer care.

The framework supports:

- **aspiring lung cancer navigators and coordinators**, by outlining the qualifications, skills and capabilities needed for the role
- **current navigators and coordinators**, by helping them reflect on practice, identify development priorities and discuss these with managers
- **line managers**, by providing a structure for conversations about competencies, development needs and career goals
- **employers**, by clarifying the navigator and coordinator role and its contribution to effective service delivery and improved outcomes
- **policy makers**, by demonstrating how the role supports better care, improved outcomes and delivery of the National Health Service's 10-year health plan, Fit for the Future.

 [Please click here to find out more.](#)

 [Click here to view and download the framework.](#)

 [Click here to listen to a podcast about the framework.](#)

GO2 LAUNCHES LUNG CANCER NAVIGATION GUIDE

GO2 for Lung Cancer has launched a new open-access textbook titled *Lung Cancer Navigation and Care: A Comprehensive Guide for Navigators and Allied Health Professionals*.


The textbook is the first site-specific, comprehensive clinical guide for lung cancer navigation in the United States. It is designed to support navigators and allied health professionals with essential knowledge, evidence-based approaches and practical tools.

Each chapter is written by multidisciplinary experts and offers up-to-date, evidence-based content. The guide includes real-world case examples, key takeaways, suggested readings and practical resources that can be applied in everyday practice. Together, the chapters provide a clear roadmap to guide patients through

screening, diagnosis, treatment, survivorship and supportive care.

The textbook also addresses the disproportionate impact of lung cancer on Black, Indigenous and other communities of colour. These populations face higher risk, are more likely to be diagnosed at a later stage, and often have reduced access to new treatments, leading to poorer outcomes.

 [Please click here to find out more.](#)

 [Please click here to download Lung Cancer Navigation and Care.](#)

BIOMARKER TESTS CONCERN IN BULGARIA

Cancer experts and patient organisations, including GLCC member APOZ, have raised concerns that many people in Bulgaria are being denied potentially life-saving biomarker tests.

At a press conference titled Cancer can be controlled. Bureaucracy – not!, the groups revealed that in 2024 the National Health Insurance Fund (NHIF) spent over 1.35 billion Bulgarian lev (BGN) – around 820 million US dollars – on treatments for malignant diseases, life-threatening haemorrhages and emergency surgeries. Of this, more than 1 billion BGN (\$600 million USD) was spent on oncology drugs alone.

However, cancer patients must usually undergo biomarker testing before accessing innovative cancer therapies. But changes to the NHIF Budget Act for 2026 and gaps in the current regulatory framework are preventing people in Bulgaria from accessing these diagnostic tests.



This lack of access may be contributing to Bulgaria's rising cancer mortality rate, which is increasing relative to other EU countries. Bulgaria also remains the only EU country where biomarker diagnostics for cancer are not publicly funded.

At the same time, none of the measures outlined in the country's National Plan for Combating Cancer, which was adopted in January 2023, are currently being implemented.



Please click to find out more about APOZ's work in Bulgaria.

LUNG CANCER SCREENING RESOURCES

Lung Foundation Australia has shared valuable resources following the launch of Australia's National Lung Cancer Screening Programme in 2025.

To support the programme's development, the organisation submitted a formal report in its favour, which is available to [read here](#).

It also launched the [Lung Cancer Blueprint: The Next Breath](#), calling on the Australian government to fund and implement a targeted national screening programme.

In the lead-up to the programme's launch, Lung Foundation Australia

collaborated with the Australian government and the National Aboriginal Community Controlled Health Organisation to develop comprehensive, accredited [eLearning for the healthcare workforce](#).

Today, the organisation continues to lead efforts to ensure priority populations can access the programme. This includes working closely with key stakeholders and establishing the [Lung Cancer Screening Consumer Committee](#) to guide patient engagement and support.



Please click here to find out more about Lung Foundation Australia's work.

SHORT VIDEOS ON BIOMARKERS RELEASED



Fundación Pacientes de Cáncer de Pulmón of Argentina has released 10 short, easy-to-watch videos tackling common myths about lung cancer and biomarker testing.

The videos explain often misunderstood topics and aim to boost awareness and understanding of biomarkers and how tests detect them.

The charity highlights the growing importance of biomarkers in lung cancer care, noting that they are set to play an increasingly central role in patients' treatment pathways.



Please click here to watch the videos.

HONG KONG MEMBER'S 2025 REVIEW AND MESSAGE



Cancer Information Network of Hong Kong, which joined the GLCC in 2025, has shared highlights from the past year and a message for fellow GLCC members.

We proudly hosted the **Lung Cancer Medicine Symposium**, promoting collaboration between Chinese and

Western medicine. The event featured renowned experts and drew over 500 professionals.

We also organized **seminars** in partnership with hospitals in Shenzhen, China, and Hong Kong University. These facilitated valuable discussions on treatments and diagnoses among healthcare professionals.

Our **Facebook Live sessions** extended our reach further, providing public education on lung cancer while addressing stigma and raising awareness.

We implemented an **LDCT programme** to highlight the importance of early detection

and launched a **Quality of Life programme**, offering workshops and activities to empower individuals living with lung cancer.

This year, we attended our **first GLCC meeting**. It was an eye-opening experience that showcased the incredible energy and dedication of the global lung cancer community.

Through these initiatives, we have worked to foster understanding, support and effective treatment solutions for lung cancer patients.

Together, we are dedicated to creating a brighter future for everyone impacted by lung cancer. We look forward to more learning and collaboration in 2026.

LUNG CANCER AWARENESS MONTH HIGHLIGHTS

Across the globe, GLCC members took action in November 2025 to get people talking about the world's biggest cancer killer. Here are just a few of the highlights.



India

Lung Connect India Foundation organised a wide range of activities, including a campaign called *The Shadow and the Light: Finding Hope in Every Hue*. It featured patients and caregivers sharing how they navigated the dark and brighter sides of lung cancer.



Australia

Lung Foundation Australia's Shine a Light on Lung Cancer campaign highlighted the challenges people with lung cancer face and the progress being made in research, treatment and care.



Netherlands

Longkanker Nederland launched the campaign *Anyone with lungs can get lung cancer*. To underline the importance of awareness, early detection and quality care, it highlighted that lung cancer can affect anyone, not only people who have smoked.



Canada

Lung Cancer Canada organised a series of awareness activities, including a forum examining the systemic delays that lung cancer patients face from diagnosis to treatment.



Please click on a member's name to find out more about their LCAM activities.

LUNG CANCER MEDIA ROUND-UP

SEVEN MILLION CANCERS A YEAR ARE PREVENTABLE

A report by the International Agency for Research on Cancer, part of the World Health Organization, estimates 37% of cancers caused by infections, lifestyle choices and environmental pollutants are avoidable.

The report, published in the journal *Nature Medicine*, showed lung cancer (linked to smoking and air pollution) stomach cancer (linked to *H. pylori* infection) and cervical cancer (linked to HPV infection) made up nearly half of all preventable cases of cancer.



Please click here for more information

EXPLORING LUNG CANCER SCREENING IN THE EU

The future of lung cancer screening across Europe was explored at an event held at the European Parliament on 18 November 2025.

Organised by the European Respiratory Society (ERS), European Lung Foundation (ELF) and European Society of Radiology (ESR), the meeting brought together health experts, screening participants, patient advocates and policymakers.

Discussions focused on the progress made in lung cancer screening across the European Union and how EU-funded research can be translated into real-world, life-saving practice.



Please click here for more information.

NEW EXERCISE STUDY IN NORWAY

Lung cancer clinicians in Norway have launched 4MoreCure, a new study exploring how exercise and diet can support people living with lung cancer.

The study examines whether structured physical activity and personalised nutritional guidance can improve quality of life and physical function.

Findings from the study will help identify effective approaches and potentially inform a larger, randomised study in the future.



Please click here for more information.
GOOGLE TRANSLATE

LUCE PUBLISHES MENTAL HEALTH REPORT

Lung Cancer Europe (LuCE) launched a new report in November 2025 titled *Mental Health and Lung Cancer*.


Based on data from 2,204 participants across 31 countries, the report is the largest global survey to date on the psychological and emotional impact of lung cancer.

The findings highlight the levels of distress, fear, and isolation that often go unrecognised in cancer care, and how many people are left without the mental health support they need.

The goal of this report is to better understand the emotional and psychological needs of those affected, and to provide clear, practical recommendations for better integrating mental health support into cancer care.



Please click here for more information.



ENCOURAGING RESULTS FROM LUNG CANCER SCREENING IN CROATIA

Analysis of Croatia's national lung cancer screening programme shows promising early results and progress toward life-saving outcomes.

In the five years since Croatia became the first European country to launch a national programme, half of the population at increased risk has been screened.

From October 2020 to August 2025, 70,129 LDCT scans were performed. The first analysis detected 685 malignant tumours, with 35% diagnosed at stage I, offering patients the best chance for effective treatment.

Beyond detecting pulmonary nodules, LDCT has also revealed other chest abnormalities, providing valuable insights into participants' overall health.



Please click here for more information.



Please click here to watch a short video on the screening programme's results.

LUNG CANCER MEDIA ROUND-UP

HIGHLIGHTS FROM ESMO 2025

The European Society of Medical Oncology's (ESMO) annual congress was held in Berlin, Germany, in October 2025.

Findings presented at the event included:

- A trial testing the drug zongertinib as a first treatment for people with advanced lung cancer who have a HER2 genetic mutation showed that 77% of patients saw their tumours shrink.
- New data from the NorthStar trial showed that combining the EGFR-targeted therapy osimertinib with radiation or surgery significantly prolonged progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC) compared to osimertinib alone.



Please click here to watch an IASLC podcast about ESMO 2025 highlights.

WOMEN AND LUNG CANCER RESEARCH BILL ADVANCES IN US

In the US, the Women and Lung Cancer Research and Preventive Services Act of 2025 has moved forward in Congress, marking progress on efforts to better understand and address lung cancer in women.

The bipartisan legislation will hopefully direct the Department of Health and Human Services to lead an interagency review of research gaps, access to preventive services and public awareness needs.

This could help to identify opportunities to accelerate research, expand prevention and improve education on lung cancer among women and underserved populations.



Please click here for more information.

LUNG CANCER VACCINE TRIAL SET TO BEGIN

Cancer Research UK has awarded up to £2.06 million to researchers at the University of Oxford and University College London to test a world-first lung cancer vaccine, LungVax.

The four-year phase I trial, starting this summer, will determine the optimal dose for people at high risk of lung cancer and assess potential side effects.

LungVax uses similar technology to the Oxford/

ROBOT-ASSISTED BRONCHOSCOPY COULD TRANSFORM DIAGNOSIS

A new robotic-assisted procedure trialled in the UK shows promise for faster, more accurate lung cancer diagnosis.

The trial involved around 200 patients with suspicious lung nodules. Using the Ion endoluminal system, clinicians navigated a tiny robotic catheter deep into hard-to-reach areas of the lungs.

Each patient's scan was transformed into a digital route map, similar to a GPS, guiding the catheter directly to the target.

Early results are encouraging; the biopsy tool was correctly placed in the lung nodule in 99% of patients (198 of 200); 92% of patients (184 of 200) received an accurate diagnosis from the tissue sample.



Please click here for more information.

STUDY ON USING EHEALTH TO SUPPORT QUALITY OF LIFE

A new review has examined how eHealth interventions affect quality of life and psychological wellbeing in people with lung cancer

The study finds that using information and communication technology to deliver health-related services could help address important gaps in lung cancer care and improve patient outcomes.

However, the review also emphasises the need for further research to develop and evaluate tailored, scalable eHealth solutions.



Please click here for more information.



Please click here for more information.

HOW TO... CREATE AN EMAIL FUNDRAISING CAMPAIGN

In our ongoing *How to ... series*, we explore why email fundraising is essential for charities and not-for-profit organisations, and provide a step-by-step guide to creating campaigns that work.



DATA PROTECTION – PLEASE READ

Email fundraising campaigns rely on the use of personal data, and with this comes a responsibility to use it lawfully, transparently and securely.

If you decide to create an email fundraising campaign, it's essential that you follow data protection regulations in your country. This will help to ensure you respect people's privacy, avoid harm and maintain credibility – all of which are vital for long-term supporter relationships and sustainable fundraising.



For information about national data protection authorities in the EU that can provide guidance, please [click here](#).



For information about worldwide national data protection authorities that can provide guidance, please [click here](#).

The above links are provided for information only. Always check which organisation is the appropriate authority in your country for legal advice on data protection.

WHY SEND A FUNDRAISING EMAIL?

Emails have a high return on investment

Email marketing is highly cost-effective, making it one of the most efficient ways to reach supporters. Personalised messages increase engagement, boosting the likelihood of donations and campaign success.

Emails are highly targeted

Emails can be tailored to individual supporters. For example, you could use first names, locations or past giving behaviour to make messages relevant. You could also segment your audience into smaller groups to ensure each email speaks directly to the recipient's interests and motivations.

Emails can be automated

Automated emails can respond to donor actions – or inaction. For example, when donors sign up to a newsletter, they could automatically receive a welcome series of emails highlighting your mission, campaigns, and ways to get involved.

Emails can be tracked and measured

Email campaigns provide clear insights into performance. Open rates, clicks and conversions can be tracked, offering data to optimise future fundraising efforts.

HOW TO CREATE A SUCCESSFUL EMAIL FUNDRAISING CAMPAIGN

1. Define your goal and audience

Start with a clear objective – whether you're raising funds for a project, responding to an urgent need or engaging supporters. Set measurable targets and a timeframe for your campaign.

Think about who your audience is and what you know about them. Tailoring emails to their interests and previous engagement with your organisation increases relevance and often drives greater response.



2. Craft a compelling message

Your email message should grab attention and communicate the 'why' behind your fundraising ask. Key elements include:

- **Subject line:** short, engaging and curiosity-inducing. A strong subject line increases open rates.
- **Body copy:** focus on the impact of donations rather than your organisation's needs. Keep sentences concise and easy to read.
- **Storytelling:** use real-life examples to create an emotional connection. Patients, community members or beneficiaries can help illustrate the difference donors make.

Balance emotional appeal with rational reasons to donate. Include facts or statistics to build credibility, but always tie them back to human impact.

3. Design your emails for readability

A well-designed email is easier to read and more likely to drive action. Key design considerations:

- **Mobile-friendly layout:** many supporters read emails on their phones. Ensure text, images and buttons display correctly on all devices.
- **Visuals:** use images or videos to highlight the people and communities you serve.
- **Call to action placement:** try to include a clear call-to-action button or link early in the email, and repeat it at the bottom. Make it easy for readers to donate immediately.

Simplicity is key: avoid clutter and keep focus on the donation ask.

4. Personalisation

Ideally, not everyone should receive the same email. Personalising your content can increase engagement and encourage greater action from your audience.

Ways to personalise emails, where you have the relevant information, include:

- using the recipient's first name
- referencing a recipient's past support for your organisation
- highlighting a specific project or cause the recipient may care about
- adjusting your ask based on the recipient's relationship with your organisation – for example, asking more from a long-term supporter than a new donor.



5. Timing and frequency

The time and day your email lands in someone's inbox can impact performance. Studies suggest sending mid-week often leads to higher engagement, but you may wish to test to find the best timing for your audience.

Avoid overloading supporters with too many emails, but also ensure your campaign is not missed by your audience.

6. Tell a story and show impact

Stories make donors feel connected to your mission. Highlight real-world outcomes, such as patients helped, programmes launched, or communities impacted. Include quotes, images or short videos, if possible. Transparency is equally important. Let donors know exactly how their contributions are used and the difference they make. Stories paired with tangible results strengthen trust and motivate action.

7. Craft a clear call to action (CTA)

Make sure every fundraising email includes a clear and compelling CTA. Use concise, action-oriented language such as:

- "Donate today to help save lives"
- "Help us reach our goal"
- "Support lung cancer patients now"

Position CTAs where readers can easily see and click them – ideally at the top, middle and end of your email.

You could also make donating easier by using pre-filled forms or one-click payment options.

8. Capturing, analysing and optimising

Collecting and analysing data from your email fundraising campaigns helps you understand what works and what doesn't.

Look at how many emails were opened, how many people clicked through to your donation page, and the number and size of gifts received.

Use these insights – and other information you can capture – to improve and test subject lines, messaging and calls to action, making future emails more relevant and effective.

9. Follow-up and donor stewardship


Ideally, your campaign shouldn't end after a donation is made. Aim to send immediate 'thank you' emails to show appreciation. Include updates on how donations are being used and the impact achieved.

Long-term engagement builds loyalty, increasing the likelihood that donors will contribute again.

10. Common mistakes to avoid

Even well-intentioned campaigns can underperform if common pitfalls aren't addressed:

- Don't overload emails with text or multiple call to actions.
- Remember your emails need to look welcoming and be accessible on mobile devices.
- Try not to send identical messages to all supporters.
- Don't forget to capture information about the performance of your emails, so you can use it to improve future campaigns.





Fundación Pacientes de Cáncer de Pulmón: www.fundacionpcp.org



LungFoundation Australia: www.lungfoundation.com.au



Oncoguia Institute: www.oncoguia.org.br



Bulgarian Anti-Cancer Patient Association (APOZ): www.oncobg.info



Canadian Lung Association: www.lung.ca

Lung Cancer Canada: www.lungcancercanada.ca

The Lung Health Foundation: www.lunghealth.ca



OnkoMaják: www.onkomajak.cz



Patientforeningen Lungekraeft: www.lungekraeft.com



La Ligue Contre le Cancer: www.ligue-cancer.net



Deutsche Krebsgesellschaft E.V: www.krebsgesellschaft.de



FairLife Lung Cancer Care: fairlifelcc.com



Cancer Information Network: cancerinformation.com.hk



Lélek-Zet: lelekzetegyesulet.hu



Lung Connect India Foundation: lungconnectindia.org



Irish Cancer Society: www.cancer.ie



The Israeli Lung Cancer Foundation: www.ilcf.org.il



ALCASE Italia: www.alcase.it

Cittadinanzattiva: www.cittadinanzattiva.it



Women Against Lung Cancer in Europe: www.womenagainstlungcancer.eu



Cancer Net Japan: www.cancernet.jp

West Japan Oncology Group (WJOG): www.wjog.jp



Frente Unido por el Cáncer de Pulmón: frentepulmon.org

Respirando Con Valor A.C: www.respirandoconvalor.org



Longkanker Nederland: www.longkankernederland.nl



LungeKreft Foreningen: www.lungekreftforeningen.no



Esperantra: www.esperantra.org



Associação Portuguesa de Luta Contra o Cancro do Pulmão: www.pulmonale.pt



Na-Vdih (Inspire): www.na-vdih.si



Campaigning for Cancer campaign4cancer.co.za/wp



Asociación Española De Afectados De Cancer De Pulmón: www.afectadoscancerdepulmon.com

La Asociación Española Contra el Cáncer: www.aecc.es



Lungcancerforeningen: www.lungcancerforeningen.se



Forum Lungenkrebs: www.facebook.com



Formosa Cancer Foundation: canceraway.org.tw



Thai Cancer Society: thaicancersociety.com



Pembe Hanim: www.pembehanım.com.tr



Asthma + Lung UK: www.asthmaandlung.org.uk

Lung Cancer Nursing UK: www.lcnuk.org

Roy Castle Lung Cancer Foundation: www.roycastle.org



CancerCare: www.cancercare.org

GO2 for Lung Cancer: www.go2.org

Lung Cancer Research Foundation: www.lungcancerresearchfoundation.org

Prevent Cancer Foundation: www.preventcancer.org

In 2026, the GLCC acknowledges the support of its sustaining partners:

Amgen, AstraZeneca, Biontech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead, Iovance, Johnson & Johnson, Merck, Novartis, Pfizer, Regeneron, Roche and Takeda.

The GLCC has prepared the content of this newsletter responsibly and carefully, but disclaims all warranties, expressed and implied, with respect to any product identified in this newsletter and bears no responsibility for the accuracy, content or legality of any website quoted in the newsletter or for that of any subsequent links. This disclaimer shall be governed by and construed in accordance with English Law under the exclusive jurisdiction of the English courts.

Editorial support: Need A Writer www.needawriter.uk Design: Hornett Design www.hornettdesign.co.uk



GLOBAL LUNG CANCER
COALITION